Grace Therapeutics (GRCE) Total Non-Current Liabilities (2019 - 2026)

Grace Therapeutics has reported Total Non-Current Liabilities for 8 years, with the latest figure at $2.8 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 34.98% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (down 34.98% YoY) and the FY2026 annual result came in at $2.8 million, down 34.98% from the prior year.
• Total Non-Current Liabilities declined to $2.8 million in Q1 2026 per GRCE's latest filing, from $3.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $20.7 million in Q3 2022 and troughed at $2.8 million in Q1 2026.
• A 5-year average of $8.9 million and a median of $7.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities soared 1188.16% in 2022, then tumbled 61.4% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at $20.1 million in 2022, then plunged by 59.3% to $8.2 million in 2023, then plunged by 35.1% to $5.3 million in 2024, then plunged by 32.2% to $3.6 million in 2025, then dropped by 23.3% to $2.8 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $2.8 million, $3.6 million, and $3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.